Table 3.
Comparison of clinical parameters for patients with in-range phosphorus during SO follow-up
| Parameter | Baseline | SO follow-up | p value |
|---|---|---|---|
| Patients with serum phosphorus ≤5.5 mg/dL for ≥3 months of SO follow-up (n = 110) | |||
| PB pills/day* | 9.3 (0.2) | 4.4 (0.2) | <0.0001 |
| Serum phosphorus, mg/dL | 5.81 (0.08) | 4.97 (0.07) | <0.0001 |
| Albumin-corrected calcium, mg/dL | 9.43 (0.06) | 9.36 (0.06) | 0.08 |
| Intact PTH, pg/mL | 406 (33) | 425 (32) | 0.4 |
| Weight, kg | 88.1 (2.3) | 87.5 (2.3) | 0.3 |
| Serum albumin, g/dL | 3.70 (0.03) | 3.64 (0.03) | <0.001 |
| Phosphorus-attuned albumin, ×103 | 0.68 (0.01) | 0.77 (0.01) | <0.0001 |
| Phosphorus-attuned nPCR, ×103 dL/kg/day | 0.18 (0.01) | 0.21 (0.01) | <0.001 |
| Serum creatinine, mg/dL | 10.3 (0.4) | 10.2 (0.4) | 0.12 |
| Kru, mL/min/1.73 m2 | 3.58 (0.38) | 3.25 (0.34) | 0.3 |
| PD Kt/V | 1.57 (0.12) | 1.73 (0.09) | 0.3 |
| Total Kt/V | 2.2 (0.1) | 2.3 (0.1) | 0.3 |
| Subset of patients with serum phosphorus >5.5 mg/dL at baseline (n = 63) | |||
| PB pills/day** | 9.9 (0.3) | 4.7 (0.3) | <0.0001 |
| Serum phosphorus, mg/dL | 6.54 (0.10) | 5.10 (0.08) | <0.0001 |
| Albumin-corrected calcium, mg/dL | 9.31 (0.09) | 9.36 (0.08) | 0.3 |
| Intact PTH, pg/mL | 430 (32) | 391 (30) | 0.087 |
| Weight, kg | 85.9 (2.7) | 87.1 (2.7) | 0.007 |
| Serum albumin, g/dL | 3.71 (0.04) | 3.63 (0.04) | 0.001 |
| Phosphorus-attuned albumin, ×103 | 0.59 (0.01) | 0.75 (0.01) | <0.0001 |
| Phosphorus-attuned nPCR, ×103 dL/kg/day | 0.17 (0.01) | 0.21 (0.01) | <0.0001 |
| Serum creatinine, mg/dL | 11.7 (0.5) | 11.3 (0.5) | 0.002 |
| Kru, mL/min/1.73 m2 | 2.71 (0.44) | 2.40 (0.37) | 0.5 |
| PD Kt/V | 1.59 (0.17) | 1.80 (0.13) | 0.3 |
| Total Kt/V | 2.0 (0.2) | 2.2 (0.1) | 0.3 |
Values are expressed as least-squared means (SE), p values compare least-squared means between treatment periods.
Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 68). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n = 42) was found to be 4.1 SO pills/day.
Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 29). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n = 34) was found to be 4.4 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathyroid hormone; SO, sucroferric oxyhydroxide; PB, phosphate binder.